Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors

/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, announced today the Journal of Clinical Oncology published...

Related Keywords

Texas ,United States ,American ,Alan Sandler ,Basu Mallick ,Meeting Program ,Mirati Therapeutics Inc ,Prnewswire Mirati Therapeutics Inc ,University Of Texas Md Anderson Cancer Center ,Exchange Commission ,Linkedin ,Facebook ,Plenary Series Program ,Twitter ,Rapid Communications ,National Comprehensive Center Network ,American Society Of Clinical Oncology ,Nasdaq ,Clinical Oncology ,Rapid Communication ,American Society ,Plenary Series ,Central Nervous System ,Shubham Pant ,Mirati Therapeutics ,Cseries Program ,Safety Of Adagrasib ,Patients With Advanced Solid Tumors Harboring ,Program Guide ,Accelerated Approval ,Time Oncology Review ,Marketing Authorization Application ,Breakthrough Therapy Designation ,Prescribing Information ,Nc ,